Arbutus Biopharma Corporation · NASDAQ:ABUS
Arbutus Biopharma — Technical Presentation (November 2020)
10 slides from Arbutus Biopharma's technical presentation, Nov 16, 2020
Slide 1: AB-729 Clinical Update
NASDAQ: ABUS www.arbutusbio.com AB - 729 Clinical Update Dr. Gaston Picchio Chief Development Officer November 16, 2020
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - looking statements fo
Slide 3: AB-729-001 Study Overview
AB - 729 - 001 Study Overview Presentation includes data available through 06 - Nov - 2020 HBV: Hepatitis B Virus | TDF: tenofovir disoproxil fumarate (≥ Day 15 Safety) Cohort A: 180 mg HBV DNA - n =4 Cohort B: 60 mg HBV DNA - n =6 Cohort C: 90 mg HBV DNA - n =6 Cohort D: 90 mg HBV DNA + n =6 Part 2
Slide 4: Baseline Characteristics
Baseline Characteristics Baseline Measure Cohort A 180 mg (N=4) Cohort B 60 mg (N=6) Cohort C 90 mg (N=6) Cohort D HBV DNA+ 90 mg (N=5*) Cohort E 60 mg Q4W (N=7) Age in years, mean (range) 42.8 (35 - 53) 48.2 (33 - 56) 54.8 (47 - 62) 43.6 (35 - 57) 45.1 (33 - 63) Male gender, n (%) 3 (75%) 3 (50%) 6
Slide 5: Repeat dosing of 60 mg every 4 weeks results in continuous mean HBsAg declines
Mean (SE) Week 12: - 1.10 (0.15) Mean (SE) Week 16: - 1.44 (0.18) Mean (SE) Week 20 : - 1.71 (0.18) Mean (SE) Week 24 : - 1.84 (0.10) [N=3] Repeat dosing of AB - 729 60 mg every 4 weeks results in continuous mean HBsAg declines beyond Week 12 5/7 HBsAg <100 IU/mL 1/7 HBsAg <10 IU/mL AB - 729 60 mg Q
Slide 6: Single dose reduces HBsAg and HBV DNA in HBV DNA positive CHB subjects
AB - 729 90 mg single dose reduces HBsAg and HBV DNA in HBV DNA positive CHB subjects 2/5 HBsAg <100 IU/mL 0/5 HBsAg <10 IU/mL HBsAg (N=5) HBV DNA (N=5) Mean HBsAg decline is similar to HBV DNA negative CHB subjects Mean Individual Week 12 - 2 .5 - 2 - 1 .5 - 1 - 0 .5 0 0 .5 0 8 10 12 Week 12 - 2 .5
Slide 7: Different response profiles following a single dose in HBV DNA positive CHB subjects
Different response profiles following a single dose of AB - 729 90 mg in HBV DNA positive CHB subjects Subject A profile Subject B profile H B s Ag HBV DNA - 2 .5 - 2 - 1 .5 - 1 - 0 .5 0 0.5 0 2 4 6 8 10 12 - 2 .5 - 2 - 1 .5 - 1 - 0 .5 0 0 .5 0 2 4 8 10 12 6 W eek ∆log 10 HBsAg and HBV DNA (IU/mL) ∆
Slide 8: Reduces HBV RNA and HBcrAg to limits of quantification or detection
AB - 729 reduces HBV RNA and HBcrAg to the limits of quantification or detection in most HBV DNA+ subjects 4/5 subjects reached <LLOQ (*) or TND (#) 2/3 subjects reached <LLOQ (*) * * * # # # Maximum reductions shown up to Week 12 in subjects with quantifiable data at baseline HBV RNA HBcrAg LLOQ =
Slide 9: Safe and well tolerated after single and repeat doses
AB - 729 was safe and well tolerated after single and repeat doses Subjects, n (%) Cohort A ( 180 mg) N= 4 Subjects with any TEAE 4 (100) Subjects with related TEAEs Grade 1 Grade 2 Grade 3 Grade 4 3 (75) 1 (25) 2 (50) 0 0 Most common related TEAEs (in ≥ 2 subjects): ALT elevation# AST elevation Hea
Slide 10: Additional data further reinforces efficacy and safety
Additional data presented today further reinforces efficacy and safety of AB - 729 In Cohort E, repeat 60 mg Q4W dosing with AB - 729 resulted in a continuous and robust HBsAg decline at week 20 ( - 1.71 log10 IU/mL). Further reductions continued beyond week 20 ( - 1.84 log10 IU/mL, N=3) ▪ No platea
Arbutus Biopharma — Technical Presentation (November 2020) on 6ix